The Biochemical and Neuroendocrine Bases of the Hyperalgesic Nocebo Effect
暂无分享,去创建一个
Fabrizio Benedetti | F. Benedetti | M. Amanzio | S. Vighetti | Martina Amanzio | Sergio Vighetti | Giovanni Asteggiano | G. Asteggiano
[1] J. Crawley,et al. International Union of Pharmacology. XXI. Structure, distribution, and functions of cholecystokinin receptors. , 1999, Pharmacological reviews.
[2] F. Benedetti,et al. Neuropharmacological Dissection of Placebo Analgesia: Expectation-Activated Opioid Systems versus Conditioning-Activated Specific Subsystems , 1999, The Journal of Neuroscience.
[3] Edward E. Smith,et al. Placebo-Induced Changes in fMRI in the Anticipation and Experience of Pain , 2004, Science.
[4] H. Fields,et al. THE MECHANISM OF PLACEBO ANALGESIA , 1978, The Lancet.
[5] M. Beinfeld. Cholecystokinin in the central nervous system: A minireview , 1983, Neuropeptides.
[6] D. Albe-Fessard,et al. Electrophysiological evidence for a release of endogenous opiates in stress-induced‘Analgesia’ in man , 1980, Brain Research.
[7] S. Gentile,et al. Neuroendocrine effects of subcutaneous sumatriptan in patients with migraine , 2001, Journal of endocrinological investigation.
[8] T. Hökfelt,et al. PD134308, a selective antagonist of cholecystokinin type B receptor, enhances the analgesic effect of morphine and synergistically interacts with intrathecal galanin to depress spinal nociceptive reflexes. , 1990, Proceedings of the National Academy of Sciences of the United States of America.
[9] F. Benedetti. Cholecystokinin Type A and Type B Receptors and Their Modulation of Opioid Analgesia , 1997 .
[10] F. Benedetti,et al. Potentiation of placebo analgesia by proglumide , 1995, The Lancet.
[11] Paul J Laurienti,et al. The subjective experience of pain: where expectations become reality. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[12] P. Petrovic,et al. Placebo and Opioid Analgesia-- Imaging a Shared Neuronal Network , 2002, Science.
[13] F. Benedetti,et al. Somatotopic Activation of Opioid Systems by Target-Directed Expectations of Analgesia , 1999, The Journal of Neuroscience.
[14] N. Baber,et al. The role of CCK, caerulein, and CCK antagonists in nociception , 1989, Pain.
[15] Tor D. Wager,et al. Placebo effects in laser-evoked pain potentials , 2006, Brain, Behavior, and Immunity.
[16] C. Büchel,et al. Mechanisms of Placebo Analgesia , 2005 .
[17] Luana Colloca,et al. Placebos and painkillers: is mind as real as matter? , 2005, Nature Reviews Neuroscience.
[18] M Schulzer,et al. Expectation and Dopamine Release: Mechanism of the Placebo Effect in Parkinson's Disease , 2001, Science.
[19] D. Price,et al. Potentiation of Systemic Morphine Analgesia in Humans by Proglumide, a Cholecystokinin Antagonist , 1985, Anesthesia and analgesia.
[20] G. Allais,et al. Psychological Aspects of Weekend Headache Sufferers in Comparison with Migraine Patients , 1989, Headache.
[21] S. Iversen,et al. Enhancement of morphine analgesia and prevention of morphine tolerance in the rat by the cholecystokinin antagonist L-364,718. , 1988, European journal of pharmacology.
[22] Jacqueline N. Crawley,et al. Biological actions of cholecystokinin , 1994, Peptides.
[23] G. Drolet,et al. Cholecystokinin and endogenous opioid peptides: Interactive influence on pain, cognition, and emotion , 2005, Progress in Neuro-Psychopharmacology and Biological Psychiatry.
[24] Luana Colloca,et al. Placebo-responsive Parkinson patients show decreased activity in single neurons of subthalamic nucleus , 2004, Nature Neuroscience.
[25] K. Stengaard-Pedersen,et al. Localization and opiate receptor binding of enkephalin, CCK and ACTH/β-endorphin in the rat central nervous system , 1981, Peptides.
[26] Howard L Fields,et al. Isolating the Modulatory Effect of Expectation on Pain Transmission: A Functional Magnetic Resonance Imaging Study , 2006, The Journal of Neuroscience.
[27] M. Morgan,et al. Opioid and non-opioid stress analgesia from cold water swim: importance of stress severity , 1986, Brain Research.
[28] G. Lavigne,et al. Proglumide potentiates morphine analgesia for acute postsurgical pain. , 1990, Clinical pharmacology and therapeutics.
[29] F. Benedetti,et al. Conscious Expectation and Unconscious Conditioning in Analgesic, Motor, and Hormonal Placebo/Nocebo Responses , 2003, The Journal of Neuroscience.
[30] L. Watkins,et al. Cholecystokinin antagonists selectively potentiate analgesia induced by endogenous opiates , 1985, Brain Research.
[31] L. Watkins,et al. Potentiation of morphine analgesia by the cholecystokinin antagonist proglumide , 1985, Brain Research.
[32] B. Roques,et al. Modulation of opioid antinociception by CCK at the supraspinal level: evidence of regulatory mechanisms between CCK and enkephalin systems in the control of pain , 1993, British journal of pharmacology.
[33] J. Harro,et al. Evidence that CCKB receptors mediate the regulation of exploratory behaviour in the rat. , 1991, European journal of pharmacology.
[34] J. Zubieta,et al. Neurobiological Mechanisms of the Placebo Effect , 2005, The Journal of Neuroscience.
[35] M. Honda,et al. Expectation of Pain Enhances Responses to Nonpainful Somatosensory Stimulation in the Anterior Cingulate Cortex and Parietal Operculum/Posterior Insula: an Event-Related Functional Magnetic Resonance Imaging Study , 2000, The Journal of Neuroscience.
[36] M. Fournié-Zaluski,et al. Cholecystokinin B antagonists strongly potentiate antinociception mediated by endogenous enkephalins. , 1994, The Journal of pharmacology and experimental therapeutics.
[37] P. L. Munson. Adrenal Cortex , 1951, British medical journal.
[38] H. Fields,et al. Pain and the Placebo: What We Have Learned , 2005, Perspectives in biology and medicine.
[39] H. Westenberg,et al. On the significance of cholecystokinin receptors in panic disorder , 1994, Progress in Neuro-Psychopharmacology and Biological Psychiatry.
[40] M. Costa,et al. Pathway-specific patterns of the co-existence of substance P, calcitonin gene-related peptide, cholecystokinin and dynorphin in neurons of the dorsal root ganglia of the guinea-pig , 1987, Cell and Tissue Research.
[41] M. Flaten,et al. Placebo and Nocebo Responses, Cortisol, and Circulating Beta-Endorphin , 2003, Psychosomatic medicine.
[42] M. Vangel,et al. Brain Activity Associated with Expectancy-Enhanced Placebo Analgesia as Measured by Functional Magnetic Resonance Imaging , 2006, The Journal of Neuroscience.
[43] T. Dietrich,et al. Placebo in Emotional Processing— Induced Expectations of Anxiety Relief Activate a Generalized Modulatory Network , 2005, Neuron.
[44] B. Bunney,et al. Proglumide: selective antagonism of excitatory effects of cholecystokinin in central nervous system. , 1983, Science.
[45] F. Benedetti. The opposite effects of the opiate antagonist naloxone and the cholecystokinin antagonist proglumide on placebo analgesia , 1996, Pain.
[46] A. Goldstein,et al. Partial antagonism of placebo analgesia by naloxone , 1983, Pain.
[47] S. Dickerson,et al. Acute stressors and cortisol responses: a theoretical integration and synthesis of laboratory research. , 2004, Psychological bulletin.
[48] T. Hökfelt,et al. The CCK-B antagonist CI988 enhances the reflex-depressive effect of morphine in axotomized rats. , 1994, Neuroreport.
[49] Fabrizio Benedetti,et al. Blockade of nocebo hyperalgesia by the cholecystokinin antagonist proglumide , 1997, Pain.
[50] Thomas E. Nichols,et al. Placebo Effects Mediated by Endogenous Opioid Activity on μ-Opioid Receptors , 2005, The Journal of Neuroscience.
[51] J. Vanderhaeghen,et al. New peptide in the vertebrate CNS reacting with antigastrin antibodies , 1975, Nature.
[52] J. Levine,et al. Influence of the method of drug administration on analgesic response , 1984, Nature.
[53] D. Price,et al. Conditioning, Expectation, and Desire for Relief in Placebo Analgesia , 2005 .
[54] J. Lauterborn,et al. Co-localization of enkephalin and cholecystokinin in discrete areas of rat brain , 1987, Brain Research.
[55] J. Harro,et al. Anxiogenic-like action of caerulein, a CCK-8 receptor agonist, in the mouse: influence of acute and subchronic diazepam treatment , 2004, Naunyn-Schmiedeberg's Archives of Pharmacology.
[56] Darrell R. Abernethy,et al. International Union of Pharmacology: Approaches to the Nomenclature of Voltage-Gated Ion Channels , 2003, Pharmacological Reviews.
[57] M. Pohl,et al. Involvement of Cholecystokininergic Systems in Anxiety-Induced Hyperalgesia in Male Rats: Behavioral and Biochemical Studies , 2005, The Journal of Neuroscience.